Last reviewed · How we verify
Vifor and EPO
Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia.
Vifor is an intravenous iron replacement therapy that replenishes iron stores, while EPO (erythropoietin) stimulates red blood cell production to treat anemia. Used for Iron deficiency anemia, Anemia of chronic kidney disease, Anemia associated with chronic disease.
At a glance
| Generic name | Vifor and EPO |
|---|---|
| Also known as | iron-supplemented combined EPO group |
| Sponsor | Kunshan First People's Hospital Affiliated to Jiangsu University |
| Drug class | Iron replacement agent and erythropoiesis-stimulating agent (ESA) |
| Target | Iron (ferric ion) and erythropoietin receptor (EPOR) |
| Modality | Small molecule |
| Therapeutic area | Hematology |
| Phase | FDA-approved |
Mechanism of action
Vifor (ferric carboxymaltose) delivers iron directly to the body to correct iron deficiency, which is essential for hemoglobin synthesis. EPO acts as a hematopoietic agent that binds to erythropoietin receptors on bone marrow progenitor cells, stimulating erythropoiesis and increasing red blood cell count. Together, they address both iron availability and erythrocyte production in anemia management.
Approved indications
- Iron deficiency anemia
- Anemia of chronic kidney disease
- Anemia associated with chronic disease
Common side effects
- Hypertension
- Headache
- Injection site reactions
- Nausea
- Thrombotic events (with EPO)
Key clinical trials
- Effects of Early Short-term Intravenous Iron Supplements Combined EPO in Preterm Infants (PHASE4)
- Impact of Preoperative Treatment of Anemia and Iron Deficiency in Cardiac Surgery on Outcome. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Vifor and EPO CI brief — competitive landscape report
- Vifor and EPO updates RSS · CI watch RSS
- Kunshan First People's Hospital Affiliated to Jiangsu University portfolio CI